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Background: In the framework of the Bovine Spongiform Encephalopathy (BSE) surveillance programme, samples
with non-conclusive results using the OIE confirmatory techniques have been repeatedly found. It is therefore
necessary to question the adequacy of the previously established consequences of this non-conclusive result:
the danger of failing to detect potentially infected cattle or erroneous information that may affect the decision of
culling or not of an entire bovine cohort. Moreover, there is a very real risk that the underreporting of cases may
possibly lead to distortion of the BSE epidemiological information for a given country.
In this study, samples from bovine nervous tissue presenting non-conclusive results by conventional OIE techniques
(Western blot and immunohistochemistry) were analyzed. Their common characteristic was a very advanced degree of
autolysis. All techniques recommended by the OIE for BSE diagnosis were applied on all these samples in order to
provide a comparative study. Specifically, immunohistochemistry, Western blotting, SAF detection by electron microscopy
and mouse bioassay were compared. Besides, other non confirmatory techniques, confocal scanning microscopy and
colloidal gold labelling of fibrils, were applied on these samples for confirming and improving the results.
Results: Immunocytochemistry showed immunostaining in agreement with the positive results finally provided
by the other confirmatory techniques. These results corroborated the suitability of this technique which was
previously developed to examine autolysed (liquified) brain samples. Transmission after inoculation of a
transgenic murine model TgbovXV was successful in all inocula but not in all mice, perhaps due to the very
scarce PrPsc concentration present in samples.
Electron microscopy, currently fallen into disuse, was demonstrated to be, not only capable to provide a final
diagnosis despite the autolytic state of samples, but also to be a sensitive diagnostic alternative for resolving
cases with low concentrations of PrPsc.
Conclusions: Demonstration of transmission of the disease even with low concentrations of PrPsc should
reinforce that vigilance is required in interpreting results so that subtle changes do not go unnoticed. To
maintain a continued supervision of the techniques which are applied in the routine diagnosis would prove
essential for the ultimate eradication of the disease.
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Bovine Spongiform Encephalopathy (BSE) belongs to a
group of neurodegenerative diseases termed Transmissible
Spongiform Encephalopathies (TSEs). It is characterized
by a chronic course (4–5 years of incubation period)
and lethal end [1]. The causal agent is accepted to be
an abnormally folded prion protein [2], which derives
from a cellular protein (PrPc) which is present in the
nervous tissue under physiological conditions and
which, owing to a conformational change, turns into
a pathological protein (PrPsc) presenting new features
as insolubility [1], resistance to digestion [3] and exposure
of some different epitopes [4].
Accumulation of PrPsc and bilaterally symmetrical
vacuolization of the neuropil and/or neuronal perikaryon
[5] are specific TSEs features. Deposits of PrPsc appear
exclusively in affected brains, being therefore considered
as a pathognomonic finding [6] and are usually used as
tool for diagnostic aims. PrPsc detection is possible due
to its partial resistance to proteinase K digestion and
shows a characteristic glycoform pattern by applying
Western blotting techniques. PrPsc deposits appear along
with neuronal loss and gliosis, even prior to the clinical
symptoms [7] which mainly consist of apprehension or
aggressive behavior, ataxia, trouble standing up, decreased
milk production and weight loss [8].
Although BSE typically affects cattle, a rather low
transmission barrier allows its transmission through
inoculation or ingestion of affected tissues [9] to mice
[5], which are used for diagnostic aims (bioassay). It can
also affect human beings causing a variant of Creutzfeldt-
Jakob disease (vCJD) [10]. Because of this fact, since
the detection of the first case of BSE in 1986 [11] and
subsequent increase of the number of affected cows and
humans, apparently due to the contamination of cattle
fed with PrPsc [12], an intensive surveillance programme
was established to prevent the entry of contaminated
material to the alimentary chain. All bovine fallen stock
and slaughtered animals of a determined age have to be
analyzed by rapid techniques [13] in order to provide a
first rapid diagnosis. As these techniques can present a
lower sensitivity than confirmatory techniques, subse-
quently, all samples giving a positive or non-conclusive
result by rapid tests needed to be finally diagnosed by
any of the confirmatory techniques as recommended by
the Office International des Epizooties [14]: histological
assessment, immunohistochemistry, Western blotting,
Scrapie-associated fibrils (SAF) visualization by electron
microscopy or bioassay for transmissibility of the disease.
However, problems arise in relation to samples which
cannot be diagnosed by those confirmatory techniques
applied for BSE diagnosis when there is a positive or
non-conclusive result in routine tests. All and each one
of these techniques were assessed in this work by usingseveral samples which initially showed non-conclusive
results, allowing a comparative analysis which has not
been carried out previously.
Throughout this intensive programme, contrary to the
initial idea of only one BSE strain [15], new strains could
be identified presenting different behaviors with respect
to classical BSE [16,17].
The objective proposed in this study is not only to
confirm the positive or negative diagnosis of these
samples, but also to find out whether the cause of their
non-conclusive behavior by conventional techniques,
could be related to a new strain of the causal agent which
might be interfering in the result of these techniques.
Methods
The samples included in this study were 5 bovine nervous
tissues corresponding to the Spanish active surveillance
programme which had presented a non-conclusive result
by immunohistochemistry and Western blotting routinely
applied for confirming BSE cases. All the samples were
characterized by a very advanced degree of autolysis
(liquified brains).
All the confirmatory techniques established by the OIE
(immunohistochemistry, Western blotting, SAF visualiza-
tion by electron microscopy and bioassay in a murine
model) were applied on problem non-conclusive samples
and were modified in order to increase the sensitivity to
detect foreseeable low concentrations of PrPsc.
All these techniques were first set up on healthy and
BSE non autolytic samples prior to be applied on autolytic
control healthy and the five non-conclusive samples
afterwards.
Immunocytochemistry
The protocol applied was based on that described by
Monleón et al. [18] for samples presenting a very advanced
degree of autolysis (liquid state). The antibodies used
were L42 (1/500, R-Biopharm, Darmstadt, Germany),
R145 (1/500, DEFRA, UK) and F89 (1/2000, VMRD Inc,
USA). Briefly, after dilution of sample in TBS, a 40 μl
subaliquot from this dilution together with two subse-
quent serial decimal dilutions were dispensed into
Vectabond-pretreated glass slides. Twenty four hour
drying at 56°C and immersion into formalin 10% for
1 hour were applied prior to pre-treatment with 98%
formic acid, proteinase K digestion and hydrated auto-
claving before PrPsc detection using the monoclonal
antibody stated above (RT for 30 minutes). EnVision™
(DAKO, Denmark) was used as visualization system
and DAB as chromogen.
In order to enhance the immunosignal for PrPsc, a
modification of the protocol consisting of the addition of
a commercial linker (DAKO, Denmark) during 15 min
before the addition of the primary antibody and a specific
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Denmark) during 30 min before DAB visualization
(DAKO, Denmark) was also assessed.
Western blotting
The protocol followed was that published by the OIE
[19] by using 6H4 as primary antibody (1:2500; Prionics,
Zurich, Switzerland) since it showed the most sensitivity.
In order to increase the sensitivity of the technique
and to assure that PrPsc concentration was enough for
its detection, a purification and concentration treatment,
combining the protocols described by Hilmert and Diringer
[20], Hope et al. [21] and Stack et al. [22], was included.
This finally consisted of a homogenization in 10%
sarcosyl in water (pH 7.4 adjusted with NaH2PO4) and
an incubation (RT for 30 min) before adding N-octanol
to remove the foam. The homogenate was centrifuged
(22.000 g for 30 min) and the pellet was subsequently
diluted in 1% sarcosyl and 10% NaCl. This step was
repeated with another centrifugation (215.000 g for
30 min) and a subsequent dilution of the pellet in 1 ml
of 1% sarcosyl and 10% NaCl (1 h, 37°C) was carried
out. After centrifugation (9.100 g for 15 min), the pellet
diluted in the same solution was digested by proteinase K
(Roche, Switzerland; 5 μg, 2 h at 37°C). A last centrifu-
gation (9.100 g for 15 minutes) was required to obtain
the pellet which was finally resuspended in water and
subjected to the protocol of electrophoresis and immu-
notransfer detailed by the OIE.
Differentiation Western blotting technique (Bio Rad,
Ref 3551177), following the manufacturer’s protocol,
was also applied on all bovine samples with the aim of
providing their glycoform patterns and trying to identify
the causal strain in all cases.
SAF visualization by electron microscopy
Prior to the application of the protocol based on that
described by Narang and Perry [23], the same protocol of
purification and concentration used for Western blotting
methodology was used for SAF visualization.
For immunohistochemistry with colloidal gold, the pro-
tocol described by Merz et al. [24] was applied but
using L42 as the primary antibody (1/500; R-Biopharm,
Darmstadt, Germany) after following similar purification
and concentration protocol. The size of the colloidal gold
used was 10 nm.
Bioassay in murine model
Transgenic mice TgbovXV [25] were intracranially and
intraperitoneally inoculated with 20 μl and 100 μl from
each sample, respectively. The inocula had to be diluted
with physiological saline to a final concentration between
1.5% and 10% and needed to be heat treated (70°C for
15 min) to eliminate the very high cytotoxicity (in in vitroand in vivo assays) and microbial contamination present
in all the samples. The average doses of brain material
finally inoculated per mouse was between 1.7 mg and
7.2 mg.
During the incubation period, the animals were clinically
examined once every day during the first month and twice
a week until the end of the experiment. All the surviving
animals were euthanized 730 days post-inoculation (DPI),
except for those cases when the endpoint criteria dictated
a premature euthanasia.
Rules established by the German Research Council’s
guide for animal experimentation, based on European guide-
lines, were followed with respect to animal handling and
care (AKTENZEINCHEN: LALLF M-V/TSD/7221.3-2.5-
006/07).
Collected brains were divided into two portions, one
fresh part for rapid techniques (BetaPrion BSE EIA Test
Kit, Roboscreen, Germany and PLATELIA BSE Detection
Kit, Bio-Rad, USA) and the other half was fixed in forma-
lin (10%), which was transversally sliced in 5 sections [26],
for confirmatory techniques.
Immunohistochemistry on murine samples
A protocol based on that described by Hortells et al.
[27] was applied on each one of the 5 sections from all
murine samples. Briefly, after pre-treatment (98% formic
acid for 15 min, proteinase K digestion for 15 min at 37°C
and hydrated autoclaving for 2 min) and endogenous
peroxidase inhibition (0,03%, 8 min), the samples were
incubated (30 min at RT) with primary antibody: 6H4
(1/100, Prionics, Zurich, Switzerland), R145 (1/100, DEFRA,
UK) or F89 (0.5 μg/ml VMRD Inc, USA). Envision + TM
Peroxidase (DAKO; Denmark) as the visualization system
and DAB (5 min, 30%; DAKO, Denmark) as chromogen
were used.
A variation of this immunohistochemical protocol con-
sisting of linker addition (DAKO, Denmark) was also
incorporated as described for bovine samples in order
to assess whether the sensitivity could increase by using
this variation.
Moreover, an ultrasensitive protocol for immunohis-
tochemistry, Catalyzed Signal Amplification (CSA) System
(DAKO, Denmark), was further assessed according to the
manufacturers’ instructions with the same aim of trying to
increase the capability to detect low PrPsc concentrations.
Electron microscopy on murine samples
Similar protocols for electron microscopy, conventional
and with colloidal gold, as those described for bovine
samples, were applied on murine samples. In summary,
after homogenization in 10% sarcosyl in water during
30 seconds and N-octanol addition, serial centrifugations
for 30 min at 22.000 g and 215.000 g in 1% sarcoyl and
10% NaCl were followed. Proteinase K incubation for
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pellet. Then, after centrifugation and removal of super-
natant, the pellet containing the purified SAF protein
was resuspended in distilled H2O. Touch grid technique
previously described was applied in order to provide
samples on formvar carbon grids. After soaking 1% SDS
1 min and rinsing in distilled water (x5), the grids were
stained with 2% potassium phosphotungstate (pH 6.6)
prior to TEM examination (80 KV).
Confocal microscopy on murine samples
With the purpose of identifying a specific cellular popula-
tion that seemed to co-localize with PrPsc in several mice,
and suggested to be a glial cell due to its morphology and
distribution, a confocal microscopy study was carried out
following the protocol previously established [28].
On this occasion, serial 50-μm sections were immersed
in endogenous peroxidase (1%, 30 min) and Triton x-100
(0.1%, 3 hours). Pre-treatment, consisting of incubation
with 98% formic acid (15 min), proteinase K digestion
(15 min, 37°C) and hydrated autoclaving (15 min for 80°C
overnight, o.n.) was included. The sections were then
incubated (4°C o.n. with agitation) with the corresponding
monoclonal prion-specific antibody (6H4, 1/500, Prionics,
Zurich, Switzerland or F89, 0.5 μg/ml, VMRD Inc, USA)
and polyclonal GFAP (1/500, DAKO, Hamburg, Germany).
Subsequently, Streptavidin-conjugated Alexa 594 (1/200,
Invitrogen, Eugene, Oregon) and Alexa 488 (1/200,
Invitrogen, Eugene, Oregon) were respectively used as
secondary antibodies for 1 hour in darkness. Incubation
for 1 hour with IgG anti-mouse biotin (1/100 Invitrogen,
Eugene, Oregon) was performed prior to fluorochrome
addition in order to enhance the fluorescent signal for
prion protein.
Each section was assessed by confocal imaging. Serial
confocal Z-stacks were taken on a Zeiss laser-scanning
confocal microscope LSM 510 (Carl Zeiss MicroImaging,
Germany) with 10x (NA 0.3) and 20x (NA 0.5) objectives.
The fluorescence emission resulted from excitation from
488-nm and 594-nm lasers and was detected with a
two-channel multi-track configuration, using band-pass
505–530 nm and long-pass 615 nm filters, respectively.





(Cut off = 0.22)
Immunohisto
chemistry
439 Non-conclusive 0.045 Non- conclusive
440 Non-conclusive 0.049 Non- conclusive
441 Non-conclusive 0.052 Non- conclusive
442 Non-conclusive 0.056 Non- conclusive
447 Non-conclusive 0.053 Non- conclusivesample and processed by Zen 2008 software (Carl Zeiss
MicroImaging, Germany).
Results
All bovine samples had presented non-conclusive results
with the initially applied rapid technique, PrionicsW-
Check WESTERN test, since the resultant signal was
evident but did not correspond with the typical glycoform
pattern of a classical BSE agent. Additionally, HERD
CHECK BSE-SCRAPIE Antigen Test Kit EIA from IDEXX
Laboratories which were applied to all bovine samples
before inoculation in mice provided negative results since
they did not reach the cutoff of the technique (Table 1).
Because of the advanced autolysis, the histopathological
examination was impossible. And for the other confirma-
tory techniques, not all of them offered a conclusive result.
First, the result provided by Western blotting was non-
conclusive because only a slight signal could be observed,
even despite the additional protocol of PrPsc concentra-
tion and purification applied on the samples (Figure 1). In
the same way, the Western blotting protocol for agent
differentiation showed a similar non-conclusive result
with both antibodies (results not shown).
However, the immunocytochemistry applied on the
bovine samples confirmed the positive diagnosis in all of
them, because immunostaining could be observed in all
the analyzed samples (Figure 2A - E). The immunostaining
corresponded with PrPsc deposits because it did not
appear in the negative controls and their presentation
was repeated with the three different antibodies used
for every sample. Finally, the modification in the protocol
based on the inclusion of linker, did not improve the sensi-
tivity of the technique for PrPsc detection.
These results corroborate those provided by electron
microscopy which confirmed the positivity of all the sam-
ples since fibrils presenting SAF morphology and features
were visualized in all of them. Moreover, the recognition
of these fibrils by gold labelled specific primary antibodies
confirmed their correspondence with PrPsc (Figure 3A).
The appearance of these fibrils was similar to that showed
by Narang and Perry [23] and Merz et al. [24], but they
were present in a lower proportion and with a shorter
length. Additionally, the colloidal gold was not onlyof the tests performed






Positive Non- conclusive Positive
Positive Non- conclusive Positive
Positive Non- conclusive Positive
Positive Non-conclusive Positive
Positive Non- conclusive Positive
Figure 1 Western blotting corresponding to one of the bovine
sample included in the study.
Figure 2 Immunocytochemistry on bovine samples by using L42 anti
and from a healthy animal. Bar = 100 μm.
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quently appeared in pairs (Figure 3B). Specificity of col-
loidal gold particles was confirmed by total absence in
negative autolytic samples.
Regarding results with the murine bioassay, several
problems associated with the autolytic state of the samples
appeared before the inoculation. All tested samples were
heat treated to inactivate the microbial contamination and
were inoculated after dilution (1.25 - 10%) to decrease the
toxicity which could not be removed exclusively by the
use of heat treatment. A high number of animals died
during the 10 days post-inoculation period. A total of
229 mice were inoculated with the bovine homogenates,
but only 148 animals survived and were finally included
in the study. During the incubation period, 36 animals
corresponding to the five bovine suspect samples showed
clinical signs which corresponded with BSE symptoms like
ataxia, loss of balance, loss of motor coordination and
lordosis. Their appearance was late (18–24 months),
even in the one animal which finally resulted positive
by all tests applied (symptoms did not appear until
17 months). The earliest incubation period presented
by a mouse with positive immunohistochemistry wasbody. (A-E) From each one of the five samples included in the study;
Figure 3 SAF visualization by applying electron microscopy marked with colloidal gold (A; Bar = 0,2 μm) and paired particles of
colloidal gold (B; Bar = 0,2 μm) in the nervous tissue of a bovine sample. Colloidal gold particles = 10 nm.
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and 19 months, respectively. Mean incubation (± SD)
periods were 21.8 ± 2.9, 19 ± 1.8, 19 ± 4.5, 21.5 ± 2.2 and
18.6 ± 5.5, respectively.
Despite the remaining animals showed a negative
result by the applied rapid test (RoboscreenW), some
of them (73) showed a value not reaching cut off but
slightly higher (0.02 - 0.058) than the presented by
other animals (< 0.02). Specifically, all these 73 animals
belonged to those 36 presenting clinical signs or had died
before the end of the experiment due to reasons other
than TSE (Table 2).
The immunohistochemical protocol applied to murine
samples evidenced a PrPsc plaque pattern in only the one
animal which had a positive result using the RoboscreenW
test (Figure 4A). However, 18 inoculated animals (dis-
tributed in all the groups corresponding to every bovine
sample analyzed) presented granular deposits in some of
the 5 sections examined, by applying the three antibodies
used (Figure 4B - D). Moreover, 12 mice showed similar
deposits by applying two antibodies (being impossible to
obtain serial sections in these cases for the third antibody
tested). As a consequence, a total of 30 animals were
considered as positive by immunohistochemistry. It is
relevant to point out that variations applied to this
protocol consisting of the addition of the linker or the
replacement by an ultrasensitive immunohistochemistryTable 2 Number of mice that presented clinical signs, resulte
rapid test depending on the group of animals inoculated wit
Bovine sample
identification
Number of mice presenting clinical signs/
total number of inoculated mice
Number of mi
RoboscreenW
439 8 / 36
440 6 / 33
441 5 / 26
442 11 / 25
447 6 / 28did not increase the sensitivity of the technique since they
did not detect a higher number of positive animals. The
correlation between animals which presented clinical signs
and positive mice by immunohistochemistry was found
(Figure 5) in all cases except for those mice that had pre-
maturely died owing to other causes than BSE (showing
PrPsc deposits in different areas of the brain but not TSE
symptoms).
An interesting finding worthy of mention is that PrPsc
deposits seemed to be associated with a specific glial cell
population in some areas from some sections (mouse
brain). The confocal microscopy technique, applied in order
to identify this cellular type, demonstrated an evident
co-localization between PrPsc accumulation and astro-
cytes (Figure 6).
As it happened in bovine samples, results provided by
immunohistochemistry on murine samples were confirmed
by visualization of fibrils by electron microscopy. Fibrils
not only appeared in the mouse brain found positive by
the RoboscreenW test but also in other mice which had
positive immunohistochemical results but were negative
with the rapid tests. A clear difference relative to the pro-
portion of fibrils visualized, much higher in the positive
animal by rapid test than in the rest of them where only
isolated fibrils were found, was evidenced (Figure 7A).
Even so, regardless the proportion the appearance and
the size coincided with those fibrils which had beend positive by immunohistochemistry and by RoboscreenW
h homogenates from each bovine sample analyzed
ce with value higher than 0.02 by
test/ total number of inoculated mice
Number of mice IHC positive/
total number of inoculated mice
5 / 36 11 / 36
21 / 33 3 / 33
11 / 26 5 / 26
20 / 25 6 / 25
16 / 28 5 / 28
Figure 4 PrPsc immunostaining in murine samples. (A) Plaque found in the positive sample by Roboscreen test. (B) No immunostaining in a
non inoculated animal (C-E) Granular staining by immunohistochemistry in one mouse corresponding to a remaining positive bioassay sample
using the three different antibodies: 6H4 , R145, F89, respectively. Bar = 200 μm.
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gold recognizing these fibrils could unequivocally
confirm the positive diagnosis of all the samples
(Figure 7B).
Additionally, a second passage using brain material from
the only mouse showing a RoboscreenW positive and
immunodeposits in plaque provided positive results by
this same technique as well as clinical signs within 7–
8 months post-inoculation in all mice inoculated (data not
shown). These results would support the theory based
on a low PrPsc concentration in the sample which might
explain the variability of the results.Discussion
All the studied bovine samples were confirmed as BSE
positive cases thanks to the results provided by im-
munocytochemistry, electron microscopy and bioassay.
Despite all the applied techniques being standardized for
increasing their capability to detect PrPsc, the extremely
scarce concentration of PrPsc in the samples is proposed
here as the most coherent reason why non-conclusive
results (weak signal presenting an unconventional pattern)
were provided by Western blotting as well as showing
different titers in the bioassay (reflected by the lack of
100% success of transmission in all the mice included in
it). Therefore, the positive results provided by immunohis-
tochemistry on murine bioassay ultimately demonstrated
that initial samples were infectious and transmitted the
disease. This was also concluded by immunocytochem-
istry and SAF detection by electron microscopy being
applied on the initial samples. However, rapid tests and
immunoblotting did not result useful for convincingly
confirming these results.Although rapid techniques applied in this study achieved
their objective as screening tests by showing a non-
conclusive signal in the samples analyzed, they were
not able to give definite results, demonstrating a lower
sensitivity compared to some of the confirmatory tech-
niques (not all in this occasion, since immunoblotting,
despite the combined protocol described, was not able to
improve the results provided by rapid tests in terms of
sensitivity). Non-conclusive diagnosis obtained by these
techniques in the bovine as well as false negative diagnosis
in the murine samples have been previously justified on
the basis of the low PrPsc concentration and the un-
suitable selection of area to be analyzed [29]. Both are
unavoidable and intrinsic features for the samples studied
here. Overall, these findings might call into question the
recent proposal determined by the OIE which dictates
that two equal results with two different rapid techniques
are enough to give an official BSE confirmation [30].
Furthermore, the results of this study confirm immuno-
cytochemistry as a useful and rapid tool for diagnosis
in liquid state samples, solving a relevant problem in
BSE and Scrapie epidemiology.
As it had been previously impossible to apply histo-
pathological examination due to the advanced degree of
autolyisis of the analyzed samples, immunohistochemistry
was evidenced as the first and reliable technique to
diagnosis of samples included here. Immunocytochemistry
has been demonstrated here as a technique capable to
provide final results for bovine samples. Moreover, this
study first demonstrates the reliability of this technique
established by Monleón et al. [18] since their results have
been corroborated by other confirmatory techniques,
specifically, by electron microscopy and by in vivo tools
(bioassay). Confirmation of the immunocytochemical
Figure 5 Graph illustrating the survivals of the individual mice in each of the five groups showing those mice which died from
inoculum toxicity or presenting specific clinical signs of prion disease and those which were positive by immunohistochemistry.
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the possible subjectivity and non-specificity which some
authors could state for the immunocytochemical assess-
ment established, since SAF visualization has been dem-
onstrated to be exclusive to TSEs [31]. In spite of the
proportion and length of fibrils being lower than those
previously described in conventional positive cases [32],
the immunolabelling of these fibrils by colloidal gold [33]
unequivocally identified PrPsc in all of them. This slight
difference in appearance is probably associated with the
low PrPsc concentration assumed at the beginning and
finally evidenced in this study. Besides, the visualizationof paired gold deposits which seem to correspond with
PrPsc dimers described by Dourmashkin et al. [34],
supports this hypothesis, associating gold deposits to
areas of potential formation of fibrils [35]. As a conse-
quence, although it is a technique currently fallen into
disuse, SAF visualization by electron microscopy is
confirmed in this study as a technique with high sensi-
tivity despite PrPsc concentration and autolysis of the
sample, demonstrating to be useful for diagnosing this
kind of samples.
On the other hand, although the bioassay presented a
transmission rate lower than expected (only 24% of the
Figure 6 Co-localization of PrPsc deposits (red) and glial cells (green) shown by confocal microscopy (yellow). Bar = 200 μm.
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was 100% since it confirmed the positive diagnosis of
the bovine samples. The low number of affected mice,
expressed in the low percentage of animals which presented
clinical signs or positive result by diagnostic techniques,
could be explained by several reasons. Despite partly
avoiding the problem of species barrier by use of bovinized
transgenic mice [36], the autolytic state of samples could
have hampered the choice of the area of study where PrPsc
was present. Nevertheless, the main responsible factor for
this failure seems to be the low initial PrPsc concentration
due to, advancement of the protease digestion associated
with the putrefaction process, the serial dilutions and heat
treatment which had to be applied on the samples before
inoculation. This scarce PrPsc presence could elongate the
incubation period and, indirectly, cause false negatives in
those mice which died prematurely, by natural death or
euthanasia, before presenting clinical signs [37] or not
presenting enough concentration of PrPsc to be detected
by the applied techniques at that moment [38]. The fact
that the only mouse clearly considered positive by rapid
tests and the only mouse showing PrPsc plaques (as
usually seen in BSE inoculated mice) [39] belonged toFigure 7 Fibrils visualized by electron microscopy. (A) In the positive m
RoboscreenW test but positive by immunohistochemistry, marked with collthe group of animals where the highest concentration
was used for inoculation, confirms this theory.
Moreover, the presence of isolated fibrils in the mice
analyzed [40] instead of grouped fibrils visualized by elec-
tron microscopy in the only positive mouse by rapid tests
[41], would, once again, correlate with this hypothesis.
As for the variance between the presence of PrPsc de-
posits and presentation of clinical signs found in some
mice, PrPsc concentration used for inoculation could
affect the results but also other explanations arise on
this matter [42]. The possibility of a transmission of the
disease without neurological signs [43] or a possible
non-exclusive relationship between PrPsc and infectivity
[44-46] and neurodegeneration [47], among them. Besides,
the demonstration of the existence of animals as persistent
carriers [48] or with a subclinical state of the disease [47],
already described in mice with high titers of infection but
no symptoms [49], should be borne in mind. This same
lack of correlation between PrPsc and infectivity could
be reflecting in the animals with symptoms but no
PrPsc deposits [50], considering in this case that the
disease might be transmitted without detectable PrPsc
[44], even with high titers [51].ouse by RoboscreenW test (Bar = 0,2 μm) (B). In a negative by
oidal gold (Bar = 0,1 μm).
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identification of astrocytes co-locating with PrPsc were
developed here, as mentioned in Material and Methods
section. The relationship between PrPsc and glial cells
observed by conventional immunohistochemistry, was
confirmed by confocal microscopy showing an evident
co-localization. This finding would put in evidence the
possibility of the participation of these cells, possibly
across the haematoencephalic barrier [27,52], in the prion
propagation in the model used here [53].
On this occasion, it was not possible to associate the
studied samples to classical or atypical BSE owing to
the lack of success to provide a clear banding pattern
by Western blotting and/or a characteristic profile by
immunohistochemistry, the lack of reference to previous
data on incubation periods and the inability to determine
lesion profiles in the mouse line. All these facts, as it has
been stated, probably due to the very scarce concentration
of PrPsc. Otherwise, whether the agent present in samples
was atypical BSE or classical BSE with really low PrPsc
deposits and low infectivity titers was not possible to
be determined.Conclusions
In conclusion, demonstration of transmission of the disease
even with low concentrations of PrPsc [54], highlights BSE’s
ability to adopt different behavior, even sometimes similar
to Scrapie [55], should reinforce that vigilance is required
in interpreting results so that subtle changes do not go un-
noticed. Additionally, to maintain a continued supervision
of the techniques which are applied in the routine diagnosis
would prove essential for the ultimate eradication of the
disease. A study of the actual BSE presence should be con-
sidered as necessary because a state of sporadic prevalence
could exist [56] and samples without a diagnosis [57,58]
could reach the food chain, involving therefore a risk for
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